Novartis is pricing Itvisma at a wholesale acquisition cost of $2.59 million, a company spokesperson told Fierce Pharma. At ...

With a phase 3 win for a combination of its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) ...

The U.K. drug marketing watchdog has ruled that a presentation calling the European Medicines Agency (EMA) “stupid” brought ...

As the researchers behind Pfizer and Astellas' Padcev and Merck's Keytruda have taken victory laps on the heels of the ...

Less than a week after Novartis unveiled a plan to establish a “flagship manufacturing hub” in North Carolina that would add ...

The United States has revealed price reductions for the second round of | The U.S. has revealed price reductions for the ...

Maryland is becoming the home away from home for British drugmaker AstraZeneca. | Maryland is becoming the home away from ...

AstraZeneca’s Imfinzi is adding yet another landmark perioperative label to its belt with a new FDA approval that gives the ...

More than 30 agents conducted a surprise raid of Sanofi’s headquarters in Paris on Tuesday morning as part of a tax fraud ...

A short film that premiered earlier this month tracks the journeys of three people who discovered a renewed commitment to ...

The new plant will allow the company to execute end-to-end clinical- and commercial-stage production of its mRNA medicines.

Anti-vaccine sentiment is alive and well, especially in the U.S. And it was evident in recent weeks as drugmakers revealed ...